Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions

OBJECTIVE: We aim to explain why salivary lactoferrin (Lf) levels are reduced in patients suffering mild cognitive impairment (MCI) and sporadic Alzheimer's disease (sAD).(1) We also will discuss if such Lf decrease could be due to a downregulation of the sAD associated systemic immunity. BACKG...

Descripción completa

Detalles Bibliográficos
Autores principales: Bermejo‐Pareja, Félix, del Ser, Teodoro, Valentí, Meritxell, de la Fuente, Mónica, Bartolome, Fernando, Carro, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Theoretical Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984071/
https://www.ncbi.nlm.nih.gov/pubmed/32543760
http://dx.doi.org/10.1002/alz.12107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984071/
https://www.ncbi.nlm.nih.gov/pubmed/32543760
http://dx.doi.org/10.1002/alz.12107

Ejemplares similares